Executive Summary

Entrepreneurship is the process of starting a business, typically a startup company offering an

innovative product, process or service. The Entrepreneur perceives an opportunity and often
exhibits biases in taking the decision to exploit the opportunity.
A business also known as an enterprise or a firm is an organization involved in the trade of goods
and services, or both to consumers. Businesses are prevalent in capitalists economies, where
most of them are privately owned and provide goods and services to customers in exchange for
other goods, services or money.
Dr. Cyrus Poonawalla, Chairman of Poonawalla Group which includes the privately owned
Serum Institute of India, India's top biotech company and now has clearly emerged as the world's
largest vaccine manufacturer by number of doses produced and sold (more than 1.3 billion doses)
which includes Polio vaccine.
The project report shows the life story of Dr.Cyrus Poonawalla.

CHAPTER 1
INTRODUCTION AND EARLY LIFE

Chairman of Poonawalla Group which includes Serum Institute of India, India's top biotech
company and has now clearly emerged as the world's largest vaccine manufacturer by number of
doses produced and sold (more than 1.3 billion doses) which includes Polio vaccine.
"Forbes Richest Billionaire's' List released in March 2015 listed Dr. Poonawalla as the 8th richest
person in India and 208th in the world with a net worth of $ 6.6 billion".

Dr. Cyrus Poonawalla, Chairman of Poonawalla Group which includes the privately owned
Serum Institute of India, India's top biotech company and now has clearly emerged as the world's
largest vaccine manufacturer by number of doses produced and sold (more than 1.3 billion
doses) which includes Polio vaccine.

A chance conversation with a vet at the farm led Dr. Poonawalla into vaccines. At the time, the
farm's retired horses were donated to government-owned Haffkine Institute in Mumbai, which
made vaccines from horse serum. Dr. Poonawalla figured he could take up the challenge of
meeting the demand for vaccines in the country by extracting the serum from horses himself and
producing cheaper vaccines.

CYRUS POONAWALLA'S PERSONAL LIFE

Cyrus Poonawalla was born in a family whose ancient business was horse racing and they owned
Poonawalla Stud Farms. He did his schooling from Bishops School, Pune and completed his
graduation from Brihan Maharashtra College of Commerce (BMCC) in 1966. He was awarded a
PhD in 1988 by the Pune University for his thesis entitled as Improved Technology in the
Manufacture of Specific Anti-toxins and its Socio-Economic Impact on the Society. Dr
Poonawalla is married to Late Villoo Poonawalla. His wife died on 8th June 2010 due to a
massive cardiac arrest. She is survived by her husband, son Adar who is the Executive Director
(Operations)

at

the

Serum

Institute,

Adar's

wife

Natasha,

and

grandson.

BEGINNING OF DR POONAWALLA'S CAREER

By the age of 20 Dr. Poonawalla realized that horse racing had no future in India. So he
experimented with cars. He along with his friend built a $120 prototype sports car modeled on
the D-type Jaguar. But producing such cars on commercial basis would require huge capital than
they had. So Dr. Poonawalla relinquished that idea, and realized that making car for the masses is
a better choice than targeting just the elite community of society. During that time horses were
donated to government owned Haffkine Institute in Mumbai, which made vaccines using horse
serum.
Dr Poonawalla observed the scope in the serum industry. He realized that he can take upon this
challenge of producing vaccines extracting horse serum and supplying it throughout the country
at affordable prices, satisfying the demand for vaccines in the country. He with his brother
Zavaray raised $12,000 by selling horses and convinced their father to put up the rest. They set
up

their

venture

in

1966

on

12-acre

lot

and

started

producing

vaccines.

BUSINESS JOURNEY OF CYRUS POONAWALLA

1996-Dr. Poonawalla with his brother Zavary founded Serum Institue of India which
launched its first therapeutic anti-tetanus serum within just two years and started with the
production of the anti-tetanus vaccines.

1974-They began producing DTP vaccine, which protects children from diphtheria,
tetanus and pertussis and then introduced an anti-snake venom serum for snake bites.

1989-They started with the production of the Measles Vaccine M-VAC and in a year
Serum Institute became the nation's largest vaccine manufacturer.

1994-Cyrus Poonawalla's Serum Institute was commissioned by the World Health

Organization to export vaccines from India and began supplying high quality vaccines to U.N.
Agencies such as PAHO (Pan American Health Organisation) and UNICEF.

1998-By 1998 Serum Institute was supplying vaccines to over a 100 countries.

2000-By 2000 one out of every two children was vaccinated by vaccines of Serum
Institute of India.
Serum Institute Of India has over the years emerged as India's leading Biotech Company and
presently is exporting vaccines to more than 140countries around the world.

CHAPTER 2 (A)
BUSINESS PHARMACEUTICALS

In 1966 Dr. Poonawalla founded Serum Institute of India (SII) which launched its first therapeutic
anti-tetanus

serum

within

two

years,

and

began

producing

the

anti-tetanus

vaccines.

By 1974 Serum Institute introduced the DTP vaccine, which protects children from diphtheria, tetanus
and

pertussis,

followed

by

an

anti-snake-venom

serum

for

snakebites

in

1981.

In 1989 Serum Institute began the production of its Measles Vaccine M-Vac and within a year Serum
Institute became the country's largest vaccine manufacturer. In the 80s India was made self-sufficient
for Tetanus, Diphtheria and Whooping Cough vaccines thanks to the production from Serum Institute.
In 1994, Serum Institute got accredited by the World Health Organization (WHO) to export vaccines
from India and started supplying high quality vaccines to U.N. Agencies such as UNICEF (United
Nations

Children's

Fund),

PAHO

(Pan

American

Health

Organization)

From the inception, Dr. Poonawallas primary concept was not only to make life-saving drugs and
vaccines, which were in shortage in the country, but also to see that every child was protected. At that
time his dictum was "Health for all by 2000 AD". The resultant effort was the National Program of
Immunization, which is largely dependent on the vaccines manufactured by Serum Institute and now
that philosophy has proliferated worldwide to International U.N. Agencies.
By 1998 Serum Institute was exporting vaccines to over a 100 countries and by 2000 one out of every
two children in the world was vaccinated by a vaccine of Serum Institute of India.
Dr. Poonawallas strong belief in "No Compromise with Quality" and willful commitment in "Health
for All with affordable Vaccines has today lead Serum Institute to become Indias leading biotech
company and has now clearly emerged as the world's largest vaccine manufacturer by number of
doses produced and sold (more than 1.3 billion doses) which includes Polio vaccine.

CHAPTER 2 (B)
SERUM INSTITUTE OF INDIA LTD.

Serum Institute of India Ltd. is now the world's largest vaccine manufacturer by number of doses
produced and sold globally (more than 1.3 billion doses) which includes Polio vaccine as well as
Diphtheria, Tetanus, Pertussis, Hib, BCG, r-Hepatitis B, Measles, Mumps and Rubella vaccines.
It is estimated that about 65% of the children in the world receive at least one vaccine
manufactured by Serum Institute. Vaccines manufactured by the Serum Institute are accredited
by the World Health Organization, Geneva and are being used in around 140 countries across the
globe in their national immunization programs, saving millions of lives throughout the world.
Serum Institute of India is ranked as India's No. 1 biotechnology company, manufacturing highly
specialized lifesaving biological like vaccines using cutting edge genetic and cell based
technologies, antisera and other medical specialties.
Serum Institute's quality control laboratories are equipped with a wide array of sophisticated
analytical equipment such as HPLC with PDA detector, Fourier Transform Infra-Red
7

Spectrophotometer, Gas Chromatograph, Atomic Absorption Spectrophotometer, real-time PCR,

new Dionex, Karl Fischer Moisture Analyzer, ELISA Readers, Liquid Particle Counters,
Capillary Zone Electrophoresis, Bio-Plex and several other state-of-the-art instruments. The
technical team has developed systems to ensure that quality is built into the process, leading to
consistency of output.
Regular training of our FDA approved Production experts and FDA approved Testing experts
through continuous professional development has played a significant role in this direction.
Many of our experts are regularly sent for training to USA, UK, France, Netherlands, etc. This
ensures that the latest advances in production and quality testing standards are quickly
incorporated in our processes. Periodic inspections of our facilities and product approvals
obtained from the World Health Organization and from national as well as international
regulatory authorities stand as testimony of Serum Institute's commitment to quality.

CHAPTER 3 (A)
MANUFACTURED PRODUCTS BY SERUM INSTITUE

MANUFACTURED PRODUCTS
Bacterial Vaccines
Tubervac

Recombinant & Combination Vaccines

Pentavac PFS, Pentavac SD, Pentavac

Bacillus Calmette-Guerin (BCG) Vaccine

MD

I.P.
Tetanus Vaccine

Diphtheria, Tetanus, Pertussis (Whole

Cell), Hepatitis-B (rDNA) & Haemophilus

Tetanus Toxoid Vaccine (Adsorbed) I.P.

Type b Conjugate Vaccine (Adsorbed) I.P.
Dual Antigen
Quadrovax PFS, Quadrovax SD (liquid)
Diphtheria and Tetanus Vaccine (Adsorbed)
Diphtheria, Tetanus, Pertussis (Whole Cell)
I. P.
and Haemophilus Type b Conjugate
Triple Antigen
Vaccine (Adsorbed)I.P
Diphtheria, Tetanus & Pertussis Vaccine
Quadrovax (Freeze-dried)
(Adsorbed) I.P.
Diphtheria, Tetanus, Pertussis (Whole Cell)
Sii HibPro
and Haemophilus Type b Conjugate
Haemophilus type b Conjugate Vaccine I.P.
Sii Td-Vac
Vaccine (Adsorbed)I.P.
SII Q-Vac
Diphtheria and Tetanus Vaccine (Adsorbed)
Diphtheria, Tetanus, Pertussis & Hepatitisfor adults & adolescents I.P.
B Vaccine (Adsorbed)
Viral Vaccines
GeneVac-B
M-Vac
Hepatitis-B Vaccine (rDNA) I.P.
Measles Vaccine (Live) I.P. (Freeze-dried)
Tresivac
Meningococcal A Conjugate Vaccine
MenAfriVac
Measles, Mumps & Rubella Vaccine (Live)
Meningococcal A Conjugate Vaccine
I.P. (Freeze-dried)
R-Vac
(Lyophilised)
9

Rubella Vaccine (Live) I.P. (Freeze-dried)

MR-Vac
Measles & Rubella vaccine
Poliovac-PFS

Anti-Sera & Other Products

Sii Polyvalent Anti Snake Venom Serum
Snake Anti venom Serum, I.P.

Poliomyelitis Vaccine (Inactivated) I.P.

Nasovac-S

(Lyophilized)
Repoitin

Influenza Vaccine, Live Attenuated

2000IU, 4000IU, 5000IU, 6000IU, 8000IU

(Human)

& 10,000 IU
Recombinant Human Erythropoietin
(rHuEPO) Injection
Repoitin-PFS
2000IU, 3000IU, 4000IU, 5000IU,
6000IU, 8000IU & 10,000 IU
Recombinant Human Erythropoietin
(rHuEPO) Injection
SII-Onco-BCG
BCG for Immunotherapy B.P.

CHAPTER 3 (B)
MARKETED PRODUCTS BY SERUM INSTITUE
10

MARKETED PRODUCTS
Gonadotrophins
Sitrodin-HP

Other Pharma Products

Mefanorm

Highly Purified Urofollitrophin (FSH)

Mefenanic acid suspension 100 mg / 5

for Injection B.P. 75/150 I.U.

Sitrodin

ml
Mefanorm Plus

Urofollitrophin (FSH) for Injection B.P. 75

Mefenanic acid 50 mg & Paracetamol

IU/150 IU
Persinal-HP

125 mg/5 ml suspension

Mintonia

Highly Purified Menotrophin (HMG)

Zinc Acetate syrup 20 mg / 5 ml

Lacfid Capsules & Sachets

for Injection B.P. 75/150 IU

Persinal
Menotrophin for Injection B.P. 75 IU/150 IU

Probiotic combination
Frida Tablets & Suspension
Ferrous Ascorbate Tablets & Suspension
KQ-100

(Lyophilized)
Sifasi-HP
Chorionic Gonadotrophin Injection I.P.

Ubidecarenone, L-Arginine, L-Caritine,

Piperine, Omega-3 Fatty Acids,

2000/5000/10000 IU
Sifasi

Lycopene, Caroteniods & Mineral

Chorionic Gonadotrophin Injection I.P.

2000/5000/10000 IU
Other Pharma Products
Sii Somastin 250 & 3000

capsules
I-KEY 50/100 Injections
Iron Sucrose Injections
Tresil

Somatostatin Injection 250 mcg & 3 mg

(Freeze-Dried)
SN-15 Tablets
Serratiopeptidase 15 mg & Nimesulide 100

Terlipressin Injection
Sii Evatone-2
Estradiol valerate tablets
Siphene 50 mg, 100 mg & Siphene-M 25
mg.

mg tablets
SN-15 Gel
Diclofenac, Mephenesin, Methyl salicylate,

Clomiphene Citrate tablets U.S.P.

Sicriptin 1.25 mg & 2.5 mg
Bromocriptine Mesylate Tablets I.P.

11

Oleum lini & Menthol

CB-Lin 0.25 mg & 0.5 mg

SD-15 Tablets

Cabergoline Tablets.
Zendol 50 mg, 100 mg & 200 mg

Diclofenac potassium 75mg &

Danazol Capsules I.P.

Meprate 10 mg, 2.5 mg

Serratiopeptidase 15 mg tablets
SN-15 Plus
Serratiopeptidase 10 mg & Diclofenac
Potassium 50 mg tablets
Z-RD

Medroxyprogesterone Acetate Tablets

U.S.P.
Ovuloc, Ovuloc - LD
Ethinyl Estradiol and Desogestrel tablets

Rabeprazole, Domperidone & Zinc

(21 tabs) with placebo (7 tabs)

Setrosil

Carnosine capsules
D-Build
Vitamin D3 60,000 IU capsules & sachets
Limarin 70 & 140 mg Capsules &
Suspension (35mg/5ml) Silymarin

Cetrorelix Acetate for Injection 0.25 mg

Strone 50 mg, 100 mg & 200 mg
Injections
Progesterone Injections B.P.
Strone 100 mg, 200 mg & 400 mg

(Hepatoprotective)
Simrose & Simrose-1000

Capsules

Evening Primrose Oil Capsules

Pyginal

Natural Micronized Progesterone B.P.

Strone SR 200 mg & 300 mg Tablets

Pygeum africanum Capsules

Dipep Capsules & Syrup

Progesterone Sustained Release Tablets

Sibolone

Digestive enzyme preparations

Hemsi Capsules & Syrup

Tibolone Tablets

Haematinics
Logi-Cal M, Logi-Cal 250 mg, 500 mg
Tablets & Logi-Cal Suspension (150
mg/5ml)
Calcium supplements
Sinate, Sinate-OD
Doxylamine succinate, Pyridoxine & Folic
acid Tablets
12

CHAPTER 4

HORSE RACING
Dr. Poonawalla has strong ties with Indias horse racing and breeding Industry through the
familys Poonawalla Stud Farms, started by his late father and now run by him and his younger
brother Zavaray. He was the sole representative of India at the International Federation of
Horseracing Authorities (IFHA) and was a member of the Asian Racing Federation (ARF) for
more than a decade.

13

He was also elected Vice Chairman of the Asian Racing Federation and also held various
esteemed posts in the Horseracing field that include Chairman, Turf Authorities of India, Royal
Western India Turf Club, Stud Book Authority of India and Pattern Races Committee.

Today, Poonawalla Stud Farms stands as the Leading Stud Farm in the country, with 12
"Champion Breeders' Awards" (the last 7 have been won in straight succession), since the awards
'inception only17 years ago. Among other numerous achievements, the farm has bred 338
Classic winners (all India) to date (20th January 2014), including winners of 9 Indian Derbies
and 6 8Indian Classics. It is the highest stakes earning establishment in the country with over
388 home breeds earning stakes in excess of Rs. 1 million

14

The farm is divided into two separate units - the young stock division situated at Hadapsar and
the breeding division located at Theur, about 10 km and 24 km from Pune, respectively. At
present, the stud farm stands 4 stallions - with the latest and very exciting ACE to be the latest
addition - and approximately 180 broodmares. The majority of the yearlings produced each year
are sold through private sale with the Poonawalla family retaining a handful for racing.

The Poonawalla Stud Farms came up with the concept in India of the Poonawalla Breeder's
Multi-Million run along the line of the Magic Million and the Cartier Million in Australia &
Ireland. Initially the race was guaranteed for Rupees One Million but in its tenth year crossed
the Five Million mark with this years stakes being boosted up to Eight Million. The idea behind
this project was to boost Indian thoroughbred racing and breeding as well as bring in a festive
atmosphere much needed by the industry.

15

H.H. Presidents Cup, U.A.E. being presented to Dr. Cyrus Poonawalla

Strategic Discussions, H.E. Sheikh Rashid bin Mohammed Al Maktoum, with Dr. Cyrus
Poonawalla & Mr. Zavaray Poonawalla

16

Seen above - Presentation at the Breeders' Cup meet on Saturday, 7th November 2009, at
the famed Santa Anita Race Course, California, and USA.

Dr. Cyrus S. Poonawalla, India's sole representative, presenting the Damascus Stakes Trophy to
the Owner of the winning horse, Mr. George Strawbridge (also in the photo are the owners,
Trainer and jockey along with their associates)

CHAPTER 5

In addition to ensuring lowest prices for vaccines and thereby making them affordable to the
masses that otherwise would not be protected against deadly diseases such as Measeles,
Diptheria, Whooping Cough etc., Dr. Poonawalla has contributed to society in the following
ways

Beautification of the City by Instituting Parks and Gardens (for example the Gool
Poonawalla Park in Pune, two Gardens in Baramati and one Garden at Tasgaon).

Contribution in the field of education, (for example setting up of Soli Poonawalla

Memorial High School in Hadapsar and Poonawalla English Medium High School in
17

Urulikanchan, which is under construction, Dr.Cyrus Poonawalla Conference Hall at

Brihan Maharashtra College of Commerce, Pune).

Highway road improvement and providing Traffic Wardens for better transport facilities
to Industries in and around Pune. (For example the Soli Poonawalla Road).

Donation to Leprosy Hospitals (He is also an Executive Council Member of the Poona
District Leprosy Committee, which is a Public Charitable Trust).

Construction of Gool Poonawalla building for housing a large Leprosy Rehabilitation

project for leprosy cured handicapped persons.

Donations to Parsee Organizations / Agiaries

Donations to poor individuals who really are in a life-threatening situation.

Participated in Confederation of Indian Industries Program of Zero Load Shedding by

Captive Power Generation by Private Companies to make life of citizens of Pune better.
Arranging Camps with Rotary International for free rubella immunization of girls from
slum areas.

18

CHAPTER 6
AWARDS WON BY CYRUS POONAWALLA
IN THE AREA OF BIO-TECHNOLOGY

Received Gold Award from the British Medical Association for the film Snakebite in
1987.

Honored with Man of the Year Mother India International Gold Award by NRI
Institute, New Delhi, on 31st January 1991.

Dr. Poonawalla received Rajat Kumar National Award on 6th May 1992 for the best
Education/Motivational/Instructional film entitled The Triumph".

Awarded with the Punes Pride Award in 1998 for excellence in the Corporate World.

19

Excellence in Inter-American Public Health award was given by PAHO (Pan American
Health Organization) to Dr. Poonawalla's for his outstanding contribution to eliminate rubella
and congenital rubella syndrome in America.

Presented with Biospectrum Person of the year 2004 award on 10th December 2004.

Dr. Poonawalla was honored with the Lifetime Achievement Award by honorable
Prime Minister, Manmohan Singh on the ceremony of the Diamond Jubilee of Briham
Maharashtra College of Commerce on 18th March 2005.

Awarded with Padama shree from of Dr. APJ Abdul Kalam, in 2005.

Dr. Cyrus Poonawalla's- Serum Institute, was awarded with No. 1 Biotech Company of
the Year for four consecutive years from 2006 to 2009.

Bestowed with Business Leader of the Year Award for Biotech 2007 on 8th February
2007.

He was honored with Ernst and Young Entrepreneur of the Year 2007 award in the field
of Health Care and Life Sciences on 20th November 2007.

Honored with Outstanding Contribution Award in developing the pharmacy profession

in India on 13th December 2002.

IN THE AREA OF HORSE RACING

Dr. Poonawalla was honored with Lifetime Achievement Award for his enormous
contributions to horse racing and breeding, on 5th October, 2009 at the International Horse
racing Conference at Paris, France.
20

Mr. Surender Reddy, Chairman, Hyderabad Race Club presented Lifetime Achievement
Award to Dr. Cyrus Poonawalla on the occasion of the 47th running of the Indian Turf
Invitation Cup, on 25th October, 2009.

CHAPTER 7
FUTUE OF SERUM INSTITUTE

21

It is our endeavor to improve the health of the Worlds Children by preventing diseases through
immunizations. After developing the Worlds first adsorbed liquid HDC rabies vaccine at a price
that brings this Gold Standard Rabies vaccine within the reach of the majority, we continue our
relentless pursuit for conquering diseases and are in the process of developing and introducing
several vaccines in the near future.
Below is a list of products on the horizon that Serum Institute intends to manufacture in the near
future.

Rotavirus Vaccine
An oral vaccine to combat millions of clinic visits,
hospitalizations and childhood deaths due to
diarrhoea worldwide.
The product is live, bovine-human reassortant
vaccine containing serotypes G1, G2, G3, G4 and
G9.
It has completed Phase I safety trial, Phase II
immunogenicity trial and is now set to undergo a
large scale Phase III efficacy trial.
This presentation is proven heat stable and would
serve to provide good efficacy in heat challenge
conditions.

22

DTaP Vaccine
Serum Institute has initiated development of
acellular pertussis vaccine containing purified
antigenic components of B. pertussis viz.
Pertussis Toxoid (PT), Filamentous
Haemagglutinin (FHA), Pertactin.
The DTaP vaccine that is under development at
Serum Institute is being tested at NIBSC, UK and
is undergoing toxicology studies. Serum Institute
plans to develop this product for the people of the
developing world within next two years. DTP
vaccines in the near future will have combinations
of other components and the key antigen for such
combinations will be acellular pertussis
component.

Pentavalent Meningococcal Conjugate

Vaccine (A, C, Y, W-135, X)
Serum Institute is working on a thermostable
Pentavalent Meningococcal Conjugate Vaccine
(A, C, Y, W-135, X) for developing countries.
The Institute is already involved with WHO and
PATH to prevent and ultimately eliminate
epidemic group A meningococcal disease in the
African meningitis belt. Consequently, the
Institute is ideally placed to develop this new
Pentavalent Conjugate Vaccine and deliver a safe
and effective product at an affordable price to the

23

parts of the world where it is needed most.

Recombinant Human Granulocyte

Colony Stimulating Factor (GCSF)
This product is being developed by Serum
Institute for correcting chemotherapy-induced
neutropenia, leading to unacceptably low levels of
neutrophils, making the patients prone to serious
infections and sepsis and thus causing oncologists
to not be able to give patients optimal
chemotherapy for fear of serious side-effects
requiring increased hospitalisation and antibiotic
cover. The recombinant human GCSF synthesized
in an E. coli expression system initiates
proliferation and differentiation of the
haematopoietic cells, thus increasing the levels of
circulating neutrophils. A pivotal multicentric
Indian phase III clinical trial has shown this
product to be non-inferior to the innovator
product in terms of safety and efficacy in the
correction of neutropenia due to
myelosuppressive chemotherapy in patients of
solid tumors and lymphomas.

24

ErepoXen (Polysialylated
Erythropoietin)
Serum Institute is developing ErepoXen product
candidate, which is an enhanced polysialylated
form of erythropoietin , a hormone produced by
the kidneys to maintain red blood cell production
and prevent anaemia caused by chronic kidney
failure. ErepoXen uses Lipoxen's
PolyXen platform technology to attach polysialic
acid, a polymer or sialic acid (a biodegradable
sugar that is found naturally in the human body)
to protein drugs.
The findings of phase I & phase II clinical trials
suggest that the drug may be effective when
administered once monthly to patients with
chronic kidney disease, thereby achieving
maximal compliance and excellent outcome
results. Serum Institute is working closely with
Lip oxen U.K. to accelerate the commercialization
of this candidate.

Pneumococcal Polysaccharide
Conjugate Vaccine
An affordable protection against pneumococcal
serotypes most prevalent in developing countries.
Globally, numerous children die of serious
pneumococcal infections each year and majority
of these deaths occur in developing countries.
Currently pneumococcal conjugate vaccines
approved for use in children are effective against
serotypes included in the vaccine, but they do not
25

cover all pneumococcal serotypes. Besides,

financial barriers limit access to these lifesaving
vaccines in countries with highest risk of the
disease.
Serum Institute is collaborating with PATH for the
speedy development of a 10-valent PCV, focusing
on the serotypes prevalent in 70.4% of the
affected population (Asia, Africa, LAC, and
India).

Purified Vero Cell Rabies Vaccine

Serum Institute has developed a heat stable
lyophilized Vero Cell Rabies Vaccine. It is
prepared using Pitman-Moore strain of rabies
virus. The virus is propagated on vero cells and is
available in a lyophilized presentation. Vero based
purified Rabies Vaccine is specifically developed
for its intradermal use besides routine
intramuscular route.

Rabies Human Monoclonal Antibody

Serum Institute has developed a fully human IgG1
type Rabies Human Monoclonal Antibody. This
antibody is manufactured in large quantities with
consistent quality using rDNA technology. SII
RMab is safe and reliable source of anti-rabies
antibody than comparative blood derived
immunoglobulins. SII RMab is recommended as a
passive antibody for post exposure prophylaxis of
rabies.

26

HPV Vaccine
Cervical Cancer is the leading cause of female
cancer mortality worldwide. Majority of the
cervical cancer related deaths occur in the low and
middle income countries where routine
gynecological screening is minimal or absent.
Serum Institute is developing a tetravalent HPV
vaccine that includes L1 VLPs of serotypes
6,11,16,18, which is expected to give coverage of
approximately 90% against papilloma virus
prevalent in the developing world. The vaccine is
currently under development and will be available
in the near future.

27

CONCLUSION
"PROGRESS IS NOT ONLY ABOUT
HOW WE GROW.
IT IS ABOUT HOW WE MAKE A
DIFFERENCE
IN THE LIVES OF OTHERS!"
That's the guiding principal of Serum Institute of India Ltd., India's No. 1 Biotech
Company and the World's Largest Vaccine Manufacturer (by volume, more than 1.3 billion
doses) which includes Polio vaccine. They are also one of the largest suppliers of vaccines to
over a 140 countries and it is estimated that about 65% of the children in the world receive at
least one vaccine manufactured by Serum Institute of India Ltd.
Serum Institute was founded by a true visionary Dr. Cyrus S. Poonawalla, to ensure that
vaccines do not remain a luxury for children in India. Having achieved this goal, Serum Institute
started supplies of high quality, yet affordable vaccines to several countries around the world.
The impact has been large enough to make International agencies such as WHO, PATH, NIH,
NVI/RIVM and CBER/USFDA to work with Serum Institute to develop vaccines against
Meningococcal A, H1N1 Influenza, Rotavirus and other diseases. It is the mission of Serum
Institute to develop quality vaccines and offer them at inexpensive prices, thus facilitating
several countries to improve their Health Index.
Though Serum Institute has grown manifold, its achievements and philanthropically nature
acknowledged, the original goal of making available World-Class vaccines at affordable prices
remains intact and is the soul of the Organization.

28

BIBLIOGRAPHY
http://www.seruminstitute.com/content/news_mile.htm
http://www.seruminstitute.com/content/about_us.htm
http://cyruspoonawalla.com/
http://cyruspoonawalla.com/content/honorsandawards.html
http://business.mapsofindia.com/business-leaders/cyrusponawalla.html

29